Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Pharmacol Res Perspect. 2024 Feb;12(1):e01164. doi: 10.1002/prp2.1164.
Monkeypox (mpox), a virus belonging to the orthopoxvirus family, can cause a zoonotic infectious disease with morbidity and cosmetic complications. Therefore, effective antiviral drugs with appropriate safety profiles are important for the treatment of patients with mpox. To date, there is no FDA-approved drug for the treatment of mpox. However, tecovirimat, brincidofovir, and cidofovir are the candidate therapies for the management of mpox. Given the safety concerns following the use of these medications, we aimed to review evidence on the clinical considerations of mpox antiviral medications that will be useful to guide clinicians in the treatment approach. Based on the current evidence, tecovirimat has favorable clinical efficacy, safety, and side effect profile and it can be considered as first-line treatment for mpox.
猴痘（mpox），一种属于正痘病毒科的病毒，可引起具有发病率和美容并发症的人畜共患传染病。因此，对于 mpox 患者的治疗，具有适当安全性特征的有效抗病毒药物非常重要。迄今为止，尚无 FDA 批准的用于治疗 mpox 的药物。然而，tecovirimat、brincidofovir 和cidofovir 是管理 mpox 的候选疗法。鉴于这些药物使用后的安全性问题，我们旨在综述 mpox 抗病毒药物的临床注意事项的证据，这将有助于指导临床医生的治疗方法。基于目前的证据，tecovirimat具有良好的临床疗效、安全性和副作用特征，可考虑作为 mpox 的一线治疗药物。
